• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Brookline Capital Markets Hosts Biotech Symposium Today

    7/26/21 6:00:00 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials
    Get the next $BCAC alert in real time by email

    Brookline Capital Markets is hosting the Brookline Capital Markets Biotech Symposium today at the International Tennis Hall of Fame in Newport, Rhode Island. The theme of the meeting is "Transformative Biotech – Cancer, Rare Diseases, and Viruses."

    Participants include private and publicly traded biotechnology companies and a group of knowledgeable healthcare investors. The agenda includes company presentations in 1:1 and small group meetings along with relevant topical panels. Presenters include senior executives of leading biotechnology companies and key opinion leaders discussing advances in oncology, rare diseases, and infectious diseases.

    The Conference reflects Brookline's focus on the life sciences sector with a particular focus on cutting-edge companies.

    About Brookline:

    Brookline Capital Markets, a division of Arcadia Securities, LLC, is a leading healthcare-focused investment banking boutique based in New York City. Brookline provides a comprehensive suite of capital markets and strategic advisory services to cutting-edge public and private life sciences, medical technology, and diagnostics companies, as well as to Special Purpose Acquisition Companies ("SPACs") and other emerging growth enterprises. Brookline is the sponsor of Brookline Capital Acquisition Corp. (NASDAQ:BCAC), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses with a focus on life science companies in the United States and Europe.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005125/en/

    Get the next $BCAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BCAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Wong Amy covered exercise/tax liability with 2,851 shares, decreasing direct ownership by 17% to 13,637 units

    4 - Apexigen, Inc. (0001814140) (Issuer)

    12/19/22 5:57:25 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Sarena Francis Willard covered exercise/tax liability with 6,916 shares, decreasing direct ownership by 17% to 33,084 units

    4 - Apexigen, Inc. (0001814140) (Issuer)

    12/19/22 5:49:39 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Hsu Frank J. covered exercise/tax liability with 4,323 shares, decreasing direct ownership by 17% to 20,677 units

    4 - Apexigen, Inc. (0001814140) (Issuer)

    12/19/22 5:41:54 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    SEC Filings

    View All

    Amendment: SEC Form S-1/A filed by Brookline Capital Acquisition Corp.

    S-1/A - Brookline Capital Acquisition Corp II (0002102072) (Filer)

    2/10/26 5:07:10 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form 10-Q filed by Brookline Capital Acquisition Corp.

    10-Q - Apexigen, Inc. (0001814140) (Filer)

    11/14/22 5:13:36 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    Brookline Capital Acquisition Corp. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Other Events, Financial Statements and Exhibits

    8-K - Apexigen, Inc. (0001814140) (Filer)

    11/14/22 4:07:21 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apexigen to Participate in the Brookline Capital Markets Newport Symposium

    SAN CARLOS, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that Apexigen's Management will participate in the Brookline Capital Markets Newport Symposium, to be held in Newport, Rhode Island on Monday, July 18, 2022. Brookline Capital Markets Newport SymposiumFormat: Apexigen presentation and 1-on-1 meetingsDate: Monday, July 18, 2022Location: Newport, Rhode Island Please contact your Brookline Capital Markets sales representative for additional information. About Apexigen, Inc.Apexigen is a clinical-st

    7/11/22 8:00:00 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    Apexigen Announces Board Appointment and New Chair

    SAN CARLOS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen" or the "Company"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of Meenu Karson as a member and Chair of Apexigen's Board of Directors, succeeding Kenneth Fong, Ph.D., as Chair. Ms. Karson will also be nominated to serve as a member and Chair of the Board of Directors of the combined company following the planned completion of the business combination with Brookline Capital Acquisition Corp. "It has been an honor to collaborate with the talented Apexigen team and guide the Comp

    6/29/22 4:05:00 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    Apexigen Appoints William Duke as Chief Financial Officer

    SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke as Chief Financial Officer, effective immediately. Mr. Duke is a biotech industry veteran and brings over 20 years of demonstrated success and leadership in corporate finance. "We are thrilled to welcome Bill. His deep financial expertise, broad strategic experience, demonstrated success raising capital and understanding of the life science industry make him the ideal fit for Apexigen's executive team," said Xiaodon

    6/8/22 8:00:00 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Financials

    Live finance-specific insights

    View All

    Apexigen and Brookline Capital Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology Company

    - Healthcare institutional investors and insiders commit $15 million through private investment in public equity ("PIPE") - - Lincoln Park Capital has committed to purchase up to $50 million of common stock - - Proceeds to advance the Phase 2 development of Apexigen's lead asset, sotigalimab, a CD40 agonist antibody with first-in-class and best-in-class potential - - Merger expected to be completed in July 2022; combined company expected to be listed on Nasdaq under the ticker symbol "APGN" - - Joint investor conference call to discuss the proposed transaction today, Friday, March 18, 2022 at 8:30 a.m. ET - SAN CARLOS, Calif. and NEW YORK, March 18, 2022

    3/18/22 6:00:00 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Brookline Capital Acquisition Corp.

    SC 13G - Apexigen, Inc. (0001814140) (Subject)

    8/8/22 12:18:48 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G/A filed by Brookline Capital Acquisition Corp. (Amendment)

    SC 13G/A - Brookline Capital Acquisition Corp. (0001814140) (Subject)

    8/1/22 3:48:29 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G filed by Brookline Capital Acquisition Corp.

    SC 13G - Brookline Capital Acquisition Corp. (0001814140) (Subject)

    4/13/22 3:32:08 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Leadership Updates

    Live Leadership Updates

    View All

    Apexigen Announces Board Appointment and New Chair

    SAN CARLOS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen" or the "Company"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of Meenu Karson as a member and Chair of Apexigen's Board of Directors, succeeding Kenneth Fong, Ph.D., as Chair. Ms. Karson will also be nominated to serve as a member and Chair of the Board of Directors of the combined company following the planned completion of the business combination with Brookline Capital Acquisition Corp. "It has been an honor to collaborate with the talented Apexigen team and guide the Comp

    6/29/22 4:05:00 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    Apexigen Appoints William Duke as Chief Financial Officer

    SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke as Chief Financial Officer, effective immediately. Mr. Duke is a biotech industry veteran and brings over 20 years of demonstrated success and leadership in corporate finance. "We are thrilled to welcome Bill. His deep financial expertise, broad strategic experience, demonstrated success raising capital and understanding of the life science industry make him the ideal fit for Apexigen's executive team," said Xiaodon

    6/8/22 8:00:00 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials